ATE282410T1 - Thyromimetika als mittel gegen fettleibigkeit - Google Patents

Thyromimetika als mittel gegen fettleibigkeit

Info

Publication number
ATE282410T1
ATE282410T1 AT00300830T AT00300830T ATE282410T1 AT E282410 T1 ATE282410 T1 AT E282410T1 AT 00300830 T AT00300830 T AT 00300830T AT 00300830 T AT00300830 T AT 00300830T AT E282410 T1 ATE282410 T1 AT E282410T1
Authority
AT
Austria
Prior art keywords
lower alkyl
hydrogen
cycloalkyl
aryl
hydroxy
Prior art date
Application number
AT00300830T
Other languages
English (en)
Inventor
Peter Cornelius
Diane Marie Hargrove
Bradley Paul Morgan
Andrew Gordon Swick
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE282410T1 publication Critical patent/ATE282410T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Valve Device For Special Equipments (AREA)
  • Discharging, Photosensitive Material Shape In Electrophotography (AREA)
  • Refinement Of Pig-Iron, Manufacture Of Cast Iron, And Steel Manufacture Other Than In Revolving Furnaces (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
AT00300830T 1999-03-01 2000-02-03 Thyromimetika als mittel gegen fettleibigkeit ATE282410T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12201599P 1999-03-01 1999-03-01

Publications (1)

Publication Number Publication Date
ATE282410T1 true ATE282410T1 (de) 2004-12-15

Family

ID=22400061

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00300830T ATE282410T1 (de) 1999-03-01 2000-02-03 Thyromimetika als mittel gegen fettleibigkeit

Country Status (15)

Country Link
US (2) US6344481B1 (de)
EP (1) EP1036564B1 (de)
JP (1) JP2000256190A (de)
KR (1) KR100368354B1 (de)
AT (1) ATE282410T1 (de)
AU (1) AU1635300A (de)
CA (1) CA2299972C (de)
CO (1) CO5150235A1 (de)
DE (1) DE60015831T2 (de)
ES (1) ES2233282T3 (de)
HU (1) HUP0000921A3 (de)
IL (1) IL134382A0 (de)
NZ (1) NZ503122A (de)
PE (1) PE20001539A1 (de)
ZA (1) ZA200001000B (de)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716810B1 (en) * 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents
US20070203225A1 (en) * 2001-04-03 2007-08-30 Havel Peter J Method of increasing endogenous adiponectin production and leptin production
US20030008838A1 (en) * 2001-04-03 2003-01-09 Havel Peter J. Method of increasing endogenous leptin production
JP3813152B2 (ja) * 2002-03-12 2006-08-23 メルク エンド カムパニー インコーポレーテッド 置換アミド類
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US20040077650A1 (en) * 2002-10-18 2004-04-22 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
US20040122033A1 (en) * 2002-12-10 2004-06-24 Nargund Ravi P. Combination therapy for the treatment of obesity
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE547404T1 (de) 2003-09-22 2012-03-15 Msd Kk Piperidinderivate
CN1882327A (zh) * 2003-11-19 2006-12-20 症变治疗公司 含磷的新的拟甲状腺素药
EP1730310A2 (de) * 2004-03-22 2006-12-13 The Regents Of The University Of California Formulierung zur steigerung der endogenen adiponectin- und leptinproduktion
EP1734963A4 (de) 2004-04-02 2008-06-18 Merck & Co Inc Verfahren zur behandlung von menschen mit metabolischen und anthropometrischen störungen
MX2007014502A (es) 2005-05-26 2008-02-07 Metabasis Therapeutics Inc Tiromimeticos para el tratamiento de enfermedades del higado graso.
WO2006128056A2 (en) * 2005-05-26 2006-11-30 Metabasis Therapeutics, Inc. Novel phosphinic acid-containing thyromimetics
BRPI0610580B8 (pt) 2005-05-30 2021-05-25 Banyu Pharma Co Ltd composto derivado de piperidina
JPWO2007018248A1 (ja) 2005-08-10 2009-02-19 萬有製薬株式会社 ピリドン化合物
WO2007024004A1 (ja) 2005-08-24 2007-03-01 Banyu Pharmaceutical Co., Ltd. フェニルピリドン誘導体
WO2007029847A1 (ja) 2005-09-07 2007-03-15 Banyu Pharmaceutical Co., Ltd. 二環性芳香族置換ピリドン誘導体
EP1940842B1 (de) 2005-09-29 2012-05-30 Merck Sharp & Dohme Corp. Acylierte spiropiperidinderivate als modulatoren des melanocortin-4-rezeptors
JP2009512715A (ja) 2005-10-21 2009-03-26 ノバルティス アクチエンゲゼルシャフト レニン阻害剤と抗異脂肪血症剤および／または抗肥満症剤の組み合わせ
EP1944301A4 (de) 2005-10-27 2012-01-04 Msd Kk Neue benzoxathiinderivate
ES2381205T3 (es) 2005-11-10 2012-05-24 Msd K.K. Derivado espiro aza-sustituido
WO2007132475A1 (en) * 2006-05-15 2007-11-22 Cadila Healthcare Limited Selective tr-beta 1 agonist
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20090247560A1 (en) 2006-09-28 2009-10-01 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
EP2264026A4 (de) 2008-03-06 2012-03-28 Msd Kk Alkylaminopyridinderivate
WO2009119726A1 (ja) 2008-03-28 2009-10-01 萬有製薬株式会社 メラニン凝集ホルモン受容体拮抗作用を有するジアリールメチルアミド誘導体
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
JPWO2009154132A1 (ja) 2008-06-19 2011-12-01 Ｍｓｄ株式会社 スピロジアミン−ジアリールケトオキシム誘導体
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2319841A1 (de) 2008-07-30 2011-05-11 Msd K.K. (5-gliedriges)-(5-gliedriges) oder (5-gliedriges)-(6-gliedriges) kondensiertes ringcycloalkylaminderivat
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
AU2009309229B2 (en) 2008-10-27 2012-03-15 Cadila Healthcare Limited Thyroid receptor ligands
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
WO2010086878A2 (en) 2009-01-09 2010-08-05 Cadila Healthcare Limited Thyroid receptor modulators
RU2527948C2 (ru) 2009-04-20 2014-09-10 Мицубиси Танабе Фарма Корпорейшн Новый агонист бета рецептора тиреоидного гормона
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9401828B2 (en) 2010-05-20 2016-07-26 Kandou Labs, S.A. Methods and systems for low-power and pin-efficient communications with superposition signaling codes
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
RU2015106909A (ru) 2012-08-02 2016-09-27 Мерк Шарп И Доум Корп. Антидиабетические трициклические соединения
KR20150118158A (ko) 2013-02-22 2015-10-21 머크 샤프 앤드 돔 코포레이션 항당뇨병 비시클릭 화합물
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
JP2020500199A (ja) 2016-11-21 2020-01-09 バイキング・セラピューティクス・インコーポレイテッド グリコーゲン蓄積症の治療方法
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298B1 (de) 2016-12-20 2026-03-11 Merck Sharp & Dohme LLC Antidiabetische spirochromanverbindungen
AU2018280118B2 (en) 2017-06-05 2021-07-15 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis
US12090252B2 (en) 2017-09-14 2024-09-17 Riken Method for producing retinal tissues
ES3053674T3 (en) 2018-03-22 2026-01-23 Viking Therapeutics Inc Crystalline forms and methods of producing crystalline forms of a compound
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
WO2020117962A1 (en) 2018-12-05 2020-06-11 Viking Therapeutics, Inc. Compositions for the treatment of fibrosis and inflammation
CA3132804A1 (en) 2019-03-13 2020-09-17 Sumitomo Dainippon Pharma Co., Ltd. Method for evaluating quality of transplant neural retina, and transplant neural retina sheet
WO2022054925A1 (ja) 2020-09-11 2022-03-17 国立研究開発法人理化学研究所 神経網膜を含む細胞凝集体とマトリクスとを含む複合体及びその製造方法
JP7760131B2 (ja) 2020-09-11 2025-10-27 株式会社Racthera 移植用組織のための媒体
EP4428227A4 (de) 2021-11-19 2025-11-12 Riken Herstellungsverfahren für blattförmiges netzhautgewebe
CN118772088B (zh) * 2024-06-14 2025-10-03 北京农学院 2-丁烯羟酸内酯硫代乙酸酯类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315739B2 (de) * 1973-10-30 1978-05-26
JPS50124993A (de) * 1974-03-20 1975-10-01
JPS5937018B2 (ja) * 1978-06-16 1984-09-07 株式会社トクヤマ 難燃化ポリプロピレン組成物
ZA824382B (en) 1981-07-07 1984-02-29 Wyeth John & Brother Ltd Anti-obesity agents
GB8501372D0 (en) * 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
GB8519154D0 (en) 1985-07-30 1985-09-04 Ici Plc Aromatic ethers
GB8714901D0 (en) 1986-07-23 1987-07-29 Ici Plc Amide derivatives
GB8801306D0 (en) 1988-01-21 1988-02-17 Ici Plc Chemical compounds
DE69314718T2 (de) 1992-07-21 1998-02-26 Ciba Geigy Ag Oxamidsäure-Derivate als hypocholesterämische Mittel
JPH0834976A (ja) * 1994-07-25 1996-02-06 Asahi Denka Kogyo Kk 潜熱利用型蓄熱材
AU5524896A (en) * 1995-03-20 1996-10-08 Institut Pasteur De Lille Modulators of ob gene and screening methods therefor
EP0920864A1 (de) * 1997-12-03 1999-06-09 Pfizer Products Inc. Kombinationstherapie durch einen spezifischen beta-3 Agonisten und einen Appetithemmer
HK1044532A1 (zh) * 1999-03-01 2002-10-25 辉瑞产品公司 用作甲状腺受体配体的草氨酸及衍生物
US6344481B1 (en) * 1999-03-01 2002-02-05 Pfizer Inc. Thyromimetic antiobesity agents

Also Published As

Publication number Publication date
CA2299972C (en) 2003-08-19
KR100368354B1 (ko) 2003-01-24
CO5150235A1 (es) 2002-04-29
US6344481B1 (en) 2002-02-05
HUP0000921A2 (hu) 2000-12-28
DE60015831T2 (de) 2005-12-15
EP1036564A1 (de) 2000-09-20
NZ503122A (en) 2001-11-30
EP1036564B1 (de) 2004-11-17
US20020035153A1 (en) 2002-03-21
ZA200001000B (en) 2001-08-29
IL134382A0 (en) 2001-04-30
JP2000256190A (ja) 2000-09-19
ES2233282T3 (es) 2005-06-16
AU1635300A (en) 2000-09-07
KR20010006712A (ko) 2001-01-26
DE60015831D1 (de) 2004-12-23
HU0000921D0 (en) 2000-04-28
CA2299972A1 (en) 2000-09-01
PE20001539A1 (es) 2001-01-08
HUP0000921A3 (en) 2004-06-28
US6555578B2 (en) 2003-04-29

Similar Documents

Publication Publication Date Title
ATE282410T1 (de) Thyromimetika als mittel gegen fettleibigkeit
TW345575B (en) Pharmaceutical composition comprising an inhibitor for ras farnesylation and the preparation of the inhibitor compound
CY1107850T1 (el) Παραγωγα θειαδιαζολυλοπιπεραζiνης mε χρησιμοτητα στην αποτροπη ή στην αγωγη εναντι tου αλγους
EP1566379A4 (de) CHINOLINDERIVATE UND CHINAZOLINDERIVATE ALS HEMMER DER Flt3-AUTOPHOSPHORYLIERUNG UND DIESE ENTHALTENDE MEDIZINISCHE ZUSAMMENSETZUNGEN
DE69706660D1 (de) N-aminoalkyldibenzofuran-carboxamide als dopaminrezeptor-subtyp spezifische liganden
DE69229442D1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ATE165510T1 (de) Methode zur hemmung der proliferation weiche muskelzellen und der restenose
EP2170876A4 (de) Isoxazolderivate enthaltende pharmazeutische zusammensetzung zur prävention und behandlung von restenose
SG151260A1 (en) 5-substituted-2-phenylamino-benzamides as mek inhibitors
KR890005031A (ko) L-도파유도체 또는 그의 산부가염, 그의 제조방법 및 그의 용도
DE60014916D1 (de) Die Verwendung eines Benzimidazoles zur Herstellung eines Medikamentes zur Krebsvorbeugung
AU2342397A (en) N-aminoalkyldibenzothiophenecarboxamides; dopamine receptor subtype specific ligands
DE69707372D1 (de) Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
DE3888340D1 (de) Verwendung von 1,4-disubstituierten-Piperidinyl-Verbindungen zur Herstellung eines Arzneimittels zur Behandlung von Schlaflosigkeit.
DE68918991D1 (de) Anwendung von Vanillin-Derivaten zur Herstellung eines Arzneimittels zur Behandlung von Herpes simplex-Infektion.
ATE284684T1 (de) Amidderivate zur behandlung neurodegenerativer erkrankungen der netzhaut
BR0317263A (pt) Ligantes alfa2delta para o tratamento de fibromialgia e outras perturbações
DE69822626T8 (de) Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
NZ293691A (en) Use of a medicament containing an anilide compound for treatment of type i allergic diseases
DE69518706D1 (de) Verwendung von Diphenylethanderivaten zur Herstellung eines Arzneimittels zur Behandlung von Glaukom
DE60123528D1 (de) Verwendung eines Mittels zur Verbesserung der Astrozytenfunktion zur Behandlung von Parkinsons Krankheit
DE69315363D1 (de) Amphotere tricyclische Verbindungen als antihistaminische und antiallergische Mittel
EA199800085A1 (ru) Способ лечения боли висцерального происхождения, способ лечения воспалительного колита
ATE181503T1 (de) Verwendung von idazoxan und derivaten zur herstellung eines arzneimittels zur behandlung von parkinsonismus und seiner evolution
BR9708922A (pt) Piridil-e pirimidil-piperazinas no tratamento de doenças causadas por substâncias usadas em excesso

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties